UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026
UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 Contact: Brian Koopman (801) 566-1200 October 22, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports third quarter (3Q) and first nine months (9M) of calend
How this was made
The 30-second read
Why it matters
The earnings shortfall could trigger a sell‑off, but cost controls and the Orion acquisition provide a partial offset.
Market read
First‑hand earnings data for a mid‑cap medical‑device firm; likely influences sector sentiment and short‑term price action.
What to watch
The acquisition of Orion Medical adds a foothold in the UK and may drive future growth beyond the quarter.
Background
UTMD is a Nasdaq‑listed medical‑device manufacturer that recently lost its two largest customers, prompting a revenue decline.
Ticker impact
UTMD filed an 8‑K reporting its Q3 2026 and nine‑month results, showing 12% lower revenue and mixed margin changes.
likely pressure as the market prices in weaker sales and customer loss
The filing is the first public disclosure of the quarter's numbers; the 12% revenue drop is material for a mid‑cap medical device maker.
Market effects
May weigh on the broader medical device and biopharma equipment sector as customers reassess spend.
Limited to U.S. and UK markets where UTMD operates.
Modest; primarily affects investors with exposure to niche medical device stocks.
Counterpoint
If the new China distributor scales quickly, the revenue gap could close, offering upside.
Key entities
- customerPendoTECH
Former largest OEM customer whose sales dropped to zero in Q3 2026.
- subsidiary acquisitionOrion Medical Supplies Ltd
UK company acquired in August 2026, contributing $619k in Q3 sales.